Pat O'Sullivan MBA Sanofi

Pat OSullivan first joined Genzyme (subsequently acquired by Sanofi) in 2001 as Head of Manufacturing for the start-up of the Waterford drug product site and progressed to the role of General Manager in 2008. Pat oversaw the start-up and ramp up of operations including the establishment of oral dose and injectable manufacturing technology platforms employing over 600 people. In 2013 Pat moved to the US to take on the General Manager position at the Allston Landing site in Boston Mass. He led the organisation through the transformation of the site including the full remediation of the facility in accordance with the FDA Consent Decree workplan requirements. In 2016 Pat took on his present role and has successfully deployed the planning and execution processes and associated organisation to support the E2E Demand and Supply management for a growing portfolio of products focused on immunology, neurology, oncology, rare diseases and rare blood disorders.This includes the successful launches of global products such as Dupixent, and other immuno therapies. Pat has more than 30 years of experience in the biopharmaceutical industry and holds an MBA from the Open University and a BSc in Chemical Engineering from the Munster Institute of Technology.